Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer
NCT05343013Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2022; status: active, not recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05343013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343013.